Share on StockTwits

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Llew Keltner sold 10,000 shares of the stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $11.21, for a total transaction of $112,100.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 6.43% during mid-day trading on Wednesday, hitting $10.92. The stock had a trading volume of 1,009,285 shares. Raptor Pharmaceutical Corp. has a one year low of $7.12 and a one year high of $17.72. The stock’s 50-day moving average is $10.28 and its 200-day moving average is $11.7. The company’s market cap is $683.8 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $11.81 million. The company’s quarterly revenue was up 120999900.0% on a year-over-year basis. On average, analysts predict that Raptor Pharmaceutical Corp. will post $-0.71 earnings per share for the current fiscal year.

A number of research firms have recently commented on RPTP. Analysts at FBR Capital Markets cut their price target on shares of Raptor Pharmaceutical Corp. from $17.00 to $16.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Raptor Pharmaceutical Corp. from $24.00 to $18.00 in a research note on Friday, May 9th. They now have an “outperform” rating on the stock. Finally, analysts at Wedbush cut their price target on shares of Raptor Pharmaceutical Corp. from $10.00 to $7.00 in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Raptor Pharmaceutical Corp. presently has a consensus rating of “Buy” and an average target price of $14.93.

Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.